Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 2
2010 1
2011 2
2012 3
2013 4
2014 3
2015 4
2016 6
2017 1
2018 2
2019 2
2020 2
2021 6
2022 10
2023 3
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Results by year

Filters applied: . Clear all
Page 1
Trial of Deferiprone in Parkinson's Disease.
Devos D, Labreuche J, Rascol O, Corvol JC, Duhamel A, Guyon Delannoy P, Poewe W, Compta Y, Pavese N, Růžička E, Dušek P, Post B, Bloem BR, Berg D, Maetzler W, Otto M, Habert MO, Lehericy S, Ferreira J, Dodel R, Tranchant C, Eusebio A, Thobois S, Marques AR, Meissner WG, Ory-Magne F, Walter U, de Bie RMA, Gago M, Vilas D, Kulisevsky J, Januario C, Coelho MVS, Behnke S, Worth P, Seppi K, Ouk T, Potey C, Leclercq C, Viard R, Kuchcinski G, Lopes R, Pruvo JP, Pigny P, Garçon G, Simonin O, Carpentier J, Rolland AS, Nyholm D, Scherfler C, Mangin JF, Chupin M, Bordet R, Dexter DT, Fradette C, Spino M, Tricta F, Ayton S, Bush AI, Devedjian JC, Duce JA, Cabantchik I, Defebvre L, Deplanque D, Moreau C; FAIRPARK-II Study Group. Devos D, et al. N Engl J Med. 2022 Dec 1;387(22):2045-2055. doi: 10.1056/NEJMoa2209254. N Engl J Med. 2022. PMID: 36449420 Clinical Trial.
A randomized clinical trial of candesartan for cognitive impairment in Parkinson's disease.
Kulisevsky J, Martínez-Horta S, Campolongo A, Pascual-Sedano B, Marín-Lahoz J, Bejr-Kasem H, Labandeira-Garcia JL, Lanciego JL, Puig-Davi A, Horta-Barba A, Pagonabarraga J, Rodríguez-Antigüedad J. Kulisevsky J, et al. Among authors: campolongo a. Parkinsonism Relat Disord. 2023 May;110:105367. doi: 10.1016/j.parkreldis.2023.105367. Epub 2023 Mar 21. Parkinsonism Relat Disord. 2023. PMID: 36963339 Clinical Trial. No abstract available.
A divergent breakdown of neurocognitive networks in Parkinson's Disease mild cognitive impairment.
Aracil-Bolaños I, Sampedro F, Marín-Lahoz J, Horta-Barba A, Martínez-Horta S, Botí M, Pérez-Pérez J, Bejr-Kasem H, Pascual-Sedano B, Campolongo A, Izquierdo C, Gironell A, Gómez-Ansón B, Kulisevsky J, Pagonabarraga J. Aracil-Bolaños I, et al. Among authors: campolongo a. Hum Brain Mapp. 2019 Aug 1;40(11):3233-3242. doi: 10.1002/hbm.24593. Epub 2019 Apr 1. Hum Brain Mapp. 2019. PMID: 30938027 Free PMC article.
A Randomized Clinical Trial to Evaluate the Effects of Safinamide on Apathetic Non-demented Patients With Parkinson's Disease.
Kulisevsky J, Martínez-Horta S, Campolongo A, Pascual-Sedano B, Marín-Lahoz J, Bejr-Kasem H, Aracil-Bolaños I, Horta-Barba A, Puig-Davi A, Pagonabarraga J. Kulisevsky J, et al. Among authors: campolongo a. Front Neurol. 2022 Jun 2;13:866502. doi: 10.3389/fneur.2022.866502. eCollection 2022. Front Neurol. 2022. PMID: 35720066 Free PMC article.
Worldwide interest in the comet assay: a bibliometric study.
Neri M, Milazzo D, Ugolini D, Milic M, Campolongo A, Pasqualetti P, Bonassi S. Neri M, et al. Among authors: campolongo a. Mutagenesis. 2015 Jan;30(1):155-63. doi: 10.1093/mutage/geu061. Mutagenesis. 2015. PMID: 25527738
Quality measurement and benchmarking of HPV vaccination services: a new approach.
Maurici M, Paulon L, Campolongo A, Meleleo C, Carlino C, Giordani A, Perrelli F, Sgricia S, Ferrante M, Franco E; QuaVaTAR Group. Maurici M, et al. Among authors: campolongo a. Hum Vaccin Immunother. 2014;10(1):208-15. doi: 10.4161/hv.26600. Epub 2013 Oct 1. Hum Vaccin Immunother. 2014. PMID: 24084361 Free PMC article.
Cognitive and Affective Empathy in Huntington's Disease.
Puig-Davi A, Martinez-Horta S, Sampedro F, Horta-Barba A, Perez-Perez J, Campolongo A, Izquierdo-Barrionuevo C, Pagonabarraga J, Gomez-Anson B, Kulisevsky J. Puig-Davi A, et al. Among authors: campolongo a. J Huntingtons Dis. 2021;10(3):323-334. doi: 10.3233/JHD-210469. J Huntingtons Dis. 2021. PMID: 34486985
Dissociable contribution of plasma NfL and p-tau181 to cognitive impairment in Parkinson's disease.
Pagonabarraga J, Pérez-González R, Bejr-Kasem H, Marín-Lahoz J, Horta-Barba A, Martinez-Horta S, Aracil-Bolaños I, Sampedro F, Campolongo A, Rivas E, Puig-Davi A, Ruiz-Barrios I, Pérez-Pérez J, Pascual-Sedano B, Kulisevsky J. Pagonabarraga J, et al. Among authors: campolongo a. Parkinsonism Relat Disord. 2022 Dec;105:132-138. doi: 10.1016/j.parkreldis.2022.05.020. Epub 2022 Jun 8. Parkinsonism Relat Disord. 2022. PMID: 35752549
Glucocerebrosidase mutations confer a greater risk of dementia during Parkinson's disease course.
Setó-Salvia N, Pagonabarraga J, Houlden H, Pascual-Sedano B, Dols-Icardo O, Tucci A, Paisán-Ruiz C, Campolongo A, Antón-Aguirre S, Martín I, Muñoz L, Bufill E, Vilageliu L, Grinberg D, Cozar M, Blesa R, Lleó A, Hardy J, Kulisevsky J, Clarimón J. Setó-Salvia N, et al. Among authors: campolongo a. Mov Disord. 2012 Mar;27(3):393-9. doi: 10.1002/mds.24045. Epub 2011 Dec 15. Mov Disord. 2012. PMID: 22173904
Subclinical affective and cognitive fluctuations in Parkinson's disease: a randomized double-blind double-dummy study of Oral vs. Intrajejunal Levodopa.
Kulisevsky J, Bejr-Kasem H, Martinez-Horta S, Horta-Barba A, Pascual-Sedano B, Campolongo A, Marín-Lahoz J, Aracil-Bolaños I, Pérez-Pérez J, Izquierdo-Barrionuevo C, de Fàbregues O, Puente V, Crespo-Cuevas A, Calopa M, Pagonabarraga J. Kulisevsky J, et al. Among authors: campolongo a. J Neurol. 2020 Nov;267(11):3400-3410. doi: 10.1007/s00415-020-10018-y. Epub 2020 Jun 30. J Neurol. 2020. PMID: 32607644 Clinical Trial.
44 results